N-Acetylcysteine in Ischemic Hepatitis

Evidence-Based Recommendations

The American Society of Anesthesiologists recommends NAC for acute liver failure regardless of etiology (GRADE 2+ recommendation with strong agreement) to improve morbidity and mortality 1
NAC is associated with overall survival improvement (76% versus 59%, OR = 2.30, 95% CI 1.54–3.45, P <0.0001) 2
Transplant-free survival increases significantly with NAC (64% versus 26%, OR = 4.81, 95% CI 3.22–7.18, P < 0.0001) 2
Initiate NAC as early as possible when ischemic hepatitis is suspected or diagnosed, as early administration is associated with better outcomes 1
NAC dosing regimen includes a loading dose of 150 mg/kg IV over 1 hour, followed by maintenance phases 3
Monitor response and complications, including tracking liver enzymes and assessing encephalopathy grade regularly 2, 3
Consider transplant evaluation early if prothrombin time <50% or progressive liver failure, as ischemic hepatitis in cirrhosis carries poor prognosis 1, 4

NAC provides cytoprotection through multiple pathways relevant to ischemic hepatitis, including improving tissue oxygen delivery, reducing hepatic hypoxia, and providing antioxidant effects 1
NAC reduces inflammatory response and cytokine synthesis, and decreases cell death through anti-apoptotic mechanisms 1
No absolute contraindications exist for NAC in ischemic hepatitis, but caution is advised in patients with reactive airway disease due to a minimal risk of bronchospasm (1-2%) 2, 3